Table 5.

Independent risk factors for survival in locally advanced pancreatic cancer patients.

	Adjusted HR (95% CI)	P value
OS from diagnosis
CA19-9 change from diagnosis to IRE
Abnormal to abnormal	2.159 (1.1-4.2)	0.02
Abnormal to normal	REF
Induction chemotherapy duration
> 5 months	1.98 (1.02-3.86)	0.04
≤ 5 months	REF
OS from IRE
Age
≤ 61	0.4 (0.21-0.78)	0.008
> 61	REF
CA19-9 at IRE
Abnormal	2.46 (1.28-4.72)	0.007
Normal	REF
Prior radiation
No	0.49 (0.26-0.93)	0.03
Yes	REF
PFS from IRE
Age
≤ 61	0.53 (0.28-.99)	0.046
> 61	REF
Induction chemotherapy
FOLFIRINOX +gemcitabine/abraxane	0.37 (0.15-0.89)	0.027
FOLFIRINOX only	1.032 (0.468-2.275)	0.93
Gemcitabine/abraxane	REF
CA19-9 at IRE
Abnormal	2.192 (1.143-4.201)	0.018
Normal	REF

OS, overall survival; HR, hazard ratio; CI, confidence interval; CA19-9, cancer antigen 19-9; IRE, irreversible electroporation; FOLFIRINOX, folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin.

Bold values represent statistical significance with p values less than 0.05.